Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

xuna

Status: Unknown

Conditions: Time of Hematopoietic Reconstruction

Treatments: Other: comprehensive treatment regimen

Study type: Interventional

Funder types: Other

Identifiers

NCT04526223

HSCT-MF-01

Details and patient eligibility

About

Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation

1. Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF)
2. With at least two month Ruxolitinib treatment prior to transplantation
3. DAC+BF as myeloablative conditioning regimen
4. CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for mismatch donor
5. received Rux at +6d in ASCT and continued to +60d

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18-60 years old, gender is not limited;
2. Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO
3. With at least two month Ruxolitinib treatment before transplantation
4. Informed consent of the patient or his legal representative

Exclusion criteria

1. HCT-CI score≥2
2. Woman who is pregnant or nursing
3. MPN Patients who have received allogeneic hematopoietic stem cell transplantation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

treatment group

Experimental group

Description:

MF patients exposure to ruxolitinib during transplantation

Treatment:

Other: comprehensive treatment regimen